To evaluate the safety, tolerability of SIBP-A10 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
Voluntarily participate in this study and sign an informed consent form;
Age range of 18 to 75 years old (including boundary values), gender not limited;
There must be at least one measurable lesion as the target lesion;
Backfilling queue during dose escalation stage, dose expansion stage, and indication expansion stage: able to provide tumor tissue samples that meet the requirements of the protocol or undergo tumor biopsy during screening, or provide testing reports issued by legitimate testing institutions that meet the requirements;
The subject has had other malignant tumors that have not healed within the past 5 years;
Subjects with meningeal metastases;
Subjects with active brain metastases;
For anti-tumor subjects with a history of past treatment or surgery that does not comply with the protocol, or who have received treatment that does not comply with the protocol during the planned trial period